Cargando…

BRAF(V600E) Mutation-Responsive miRNA-222-3p Promotes Metastasis of Papillary Thyroid Cancer Cells via Snail-Induced EMT

BRAF mutation accounts for 50% of the PTC (papillary thyroid carcinoma) and is closely associated with high-risk clinicopathological characteristics. Increasing evidence implied that dysregulation of miRNA participated in carcinogenesis and progression of cancer. Clinical data showed the significant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Yuan, Xiang, Dapeng, Li, Weijie, Zheng, Xi, Wang, Lin, Li, Zhiyu, Chen, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148970/ https://www.ncbi.nlm.nih.gov/pubmed/35651980 http://dx.doi.org/10.3389/fendo.2022.843334

Ejemplares similares

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation
por: Han, Ying, et al.
Publicado: (2022)

Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?
por: Nucera, Carmelo, et al.
Publicado: (2012)

miR-222 expression is correlated with the ATA risk stratifications in papillary thyroid carcinomas∗
por: Xiang, Dapeng, et al.
Publicado: (2019)

Association Between Preoperative US, Elastography Features and Prognostic Factors of Papillary Thyroid Cancer With BRAF(V600E) Mutation
por: Xu, Jun-Mei, et al.
Publicado: (2020)

Snail-1 Overexpression Correlates with Metastatic Phenotype in BRAF(V600E) Positive Papillary Thyroid Carcinoma
por: Wieczorek-Szukala, Katarzyna, et al.
Publicado: (2020)

Fine Needle Biopsy Versus Core Needle Biopsy Combined With/Without Thyroglobulin or BRAF 600E Mutation Assessment for Detecting Cervical Nodal Metastasis of Papillary Thyroid Carcinoma
por: Zhang, Xiaojun, et al.
Publicado: (2021)

Radiomic Model for Determining the Value of Elasticity and Grayscale Ultrasound Diagnoses for Predicting BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wang, Yu-guo, et al.
Publicado: (2022)

The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
por: Melck, Adrienne L., et al.
Publicado: (2010)

Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Braf(v600e) Mutation: A Single Center Study of 1,207 Chinese Patients
por: Xue, Shuai, et al.
Publicado: (2019)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma
por: Ramkumar, Subramaniam, et al.
Publicado: (2021)

Nomogram based on radiomics analysis of ultrasound images can improve preoperative BRAF mutation diagnosis for papillary thyroid microcarcinoma
por: Tang, Jiajia, et al.
Publicado: (2022)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer
por: Kondrotienė, Aistė, et al.
Publicado: (2020)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

BRAF(V600E)-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT
por: Wang, Xuhong, et al.
Publicado: (2019)

MIEAP and ATG5 are tumor suppressors in a mouse model of BRAF(V600E)-positive thyroid cancer
por: Hamada, Koichiro, et al.
Publicado: (2022)

Simultaneous Hodgkin lymphoma and BRAF(V600E)-positive papillary thyroid carcinoma: A case report
por: Liu, Shu, et al.
Publicado: (2019)

Deep Small RNA Sequencing of BRAF V600E Mutated Papillary Thyroid Carcinoma With Lymph Node Metastasis
por: Yusof, Azliana Mohamad, et al.
Publicado: (2019)

Predicting factors of central lymph node metastasis and BRAF(V600E) mutation in Chinese population with papillary thyroid carcinoma
por: Zhou, Sheng Li, et al.
Publicado: (2021)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Biomarker Value of miR-221 and miR-222 as Potential Substrates in the Differential Diagnosis of Papillary Thyroid Cancer Based on Data Synthesis and Bioinformatics Approach
por: Cai, Shang, et al.
Publicado: (2022)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma
por: He, Weiman, et al.
Publicado: (2023)

How do BRAF(V600E) and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?
por: Mukhtar, Noha, et al.
Publicado: (2023)

LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma
por: Hou, Xiukun, et al.
Publicado: (2021)

Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto’s thyroiditis: a systematic review with meta-analysis
por: Janicki, Lukasz, et al.
Publicado: (2023)

Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer
por: Xia, Yuxiao, et al.
Publicado: (2022)

Can Cervical Lymph Node Metastasis Increase the Risk of Distant Metastasis in Papillary Thyroid Carcinoma?
por: Wang, Wenlong, et al.
Publicado: (2022)

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer
por: Ge, Junshang, et al.
Publicado: (2020)

Clinical Significance of PEAK1 Expression and BRAF V600E Mutation in Papillary Thyroid Cancer
por: Li, P., et al.
Publicado: (2022)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5rr38nnnqnq57bvprn5vjpuj6d